Canaccord Genuity maintains Beam Therapeutics at Buy, lowers price target to $78 from $79

Canaccord Genuity kept its Buy rating on Beam Therapeutics but reduced its price target to $78 from $79. This implies a 180.7% upside from the Nov 4 close of $27.79. Recent analyst price targets for the company range from $30 to $80.

Original reporting
Published Nov 4, 2026, 11:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Canaccord Genuity maintains Beam Therapeutics at Buy, lowers price target to $78 from $79 — source image
Decision brief

The 30-second read

$BEAMBearishLow
01

Why it matters

The modest downgrade may lead to slight sell pressure.

02

Market read

Small but actionable insight for traders monitoring biotech analyst coverage.

03

What to watch

Potential upcoming catalyst not reflected in the target change.

Relevance 5/10Novelty 4/10Timing: today

Background

Analyst price target adjustments are routine but can influence short-term trading.

Company-level read

Ticker impact

$BEAMBearishMedium confidence
Context

Canaccord Genuity lowered Beam Therapeutics' price target to $78 from $79.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

A 1.3% target cut signals reduced upside, which may temper bullish sentiment.

Market effects

Minor impact on the biotech sector as analysts adjust expectations.

Limited to U.S. biotech investors.

Low global relevance.

Counterpoint

The target cut may be overly cautious given recent trial data.

Key entities

  • Beam Therapeutics

    Biotech firm developing CRISPR-based gene editing therapies.

  • Canaccord Genuity

    Equity research firm providing coverage on BEAM.

Related articles

$BEAMHighAI 9/10

Beam Sickle Cell Therapy Meets Pivotal Goals

Beam Therapeutics reported positive pivotal trial results for risto-cel, its sickle cell treatment, meeting all primary and secondary endpoints. The trial showed patients stayed free of severe vaso-occlusive crises for at least 12 months. Beam plans to file for FDA approval by year-end 2026, aiming to be the first base-editing therapy approved in the US. The company will present detailed results at a medical meeting in 2027.